EP 3535277 A1 20190911 - THERAPEUTIC COMPOSITION DERIVED FROM ANTHOSTEMA SENEGALENSE
Title (en)
THERAPEUTIC COMPOSITION DERIVED FROM ANTHOSTEMA SENEGALENSE
Title (de)
THERAPEUTISCHE ZUSAMMENSETZUNG AUS ANTHOSTEMA SENEGALENSE
Title (fr)
COMPOSITION THÉRAPEUTIQUE DÉRIVÉE D'ANTHOSTEMA SENEGALENSE
Publication
Application
Priority
- FR 1660230 A 20161021
- FR 1750080 A 20170105
- FR 2017052891 W 20171020
Abstract (en)
[origin: WO2018073551A1] The present invention relates to a chemical composition characterized in that it comprises: - the molecule A or a physiologically acceptable salt thereof, and/or: - the molecule B or a physiologically acceptable salt thereof, said molecule A having the following formula: and the molecule B having the following formula: the molecule A or a physiologically acceptable salt thereof being biologically active and stimulating immune activity, the molecule B or a physiologically acceptable salt thereof being biologically active and stimulating immune activity .
IPC 8 full level
C07J 63/00 (2006.01); A61K 36/47 (2006.01)
CPC (source: EP US)
A23L 33/11 (2016.07 - US); A61K 31/56 (2013.01 - US); A61K 36/47 (2013.01 - EP US); A61P 31/18 (2017.12 - EP US); C07J 63/008 (2013.01 - EP); A61K 2236/17 (2013.01 - US); A61K 2236/33 (2013.01 - US); A61K 2236/51 (2013.01 - US)
Citation (search report)
See references of WO 2018073551A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
FR 3057866 A1 20180427; FR 3057866 B1 20201030; CN 110099916 A 20190806; EP 3535277 A1 20190911; FR 3057865 A1 20180427; RU 2019120255 A 20201228; RU 2019120255 A3 20201228; US 2019350995 A1 20191121; WO 2018073551 A1 20180426
DOCDB simple family (application)
FR 1750080 A 20170105; CN 201780079975 A 20171020; EP 17797397 A 20171020; FR 1660230 A 20161021; FR 2017052891 W 20171020; RU 2019120255 A 20171020; US 201716476192 A 20171020